| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.0081 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |